23 Jul, 2026
According to Straits Research the global transcriptomics market size was valued at $8.2 billion in 2025 and is projected to grow from $8.63 billion in 2026 to $12.97 billion by 2034, at a CAGR of 5.23% during the forecast period 2026–2034.
Transcriptomics is the transcriptome study, a collective term for all transcripts. A transcriptome is a complete collection of all the ribonucleic acid (RNA) molecules expressed in an organism, cell, or tissue. In addition, transcriptomics encompasses all aspects of RNA, such as transcription and expression levels, locations, functions, trafficking, and degradation. The field of genomics has established itself as a focal point of academic scientific research and clinical medicine. Significant advances in science and technology, such as precision medicine, next-generation sequencing (NGS), and RNA-sequencing, have created opportunities for public healthcare.
The introduction of sequencing technologies, especially next-generation sequencing (NGS), has revolutionized the diagnosis of genetic disorders, allowing doctors to provide even more comprehensive clinical insights. RNA-sequencing permits a more comprehensive analysis and resolution of the dynamic transcriptome. For RNA analysis, high-throughput next-generation sequencing is being modified. Recent advances in RNA-sequencing have enormously impacted sample preparation, sequencing, and data analysis. This is beneficial for profiling the transcriptome and determining the potential to explain diverse physiological and pathological parameters.
The NGS and RNA-sequencing techniques sequence millions of nucleotide fragments for transcriptome analysis. The HiSeq series of sequencers from Illumina is the primary platform for RNA-Seq because it provides high throughput, deep sequencing, fewer sequencing errors, and long enough read data advantageous for various applications. In addition, PacBio RS II is becoming increasingly popular for constructing transcriptomes with long reads.
Among precision medicine, clinical applications of transcriptomics are prostate cancer, acute lymphoblastic leukemia, and hepatocellular carcinoma. The transcriptome study is essential for identifying disease pathways and developing effective drugs. Transcriptome research aims to comprehend and elucidate how the transcripts of a cell or tissue function when they are affected by disease and in response to treatment. Precision medicine contributes to the development of pharmaceuticals and the treatment of various diseases, including cancer. These are utilized in various fields, including oncology, cell therapy, immunology, and neurology. Implementing Next-Generation Sequencing (NGS) platforms has radically altered the landscape of RNA research, which relies on the continuous development of molecular technologies. RNA-sequencing is gaining importance in clinical care for cancer patients, preclinical research, and basic science. Numerous trials related to transcriptome-based personalized oncology have been expedited by comprehending molecular mechanisms, particularly cancer.
As genomics and data analysis continue to make rapid advancements, it is essential to acknowledge the dynamic nature of this field. Older technologies are being replaced by newer technologies to comprehend the complexities of genome behavior in healthy and ill individuals with greater specificity as time passes. It is crucial to note that RNA-sequencing, microarrays, PCR, and next-generation sequencing play a significant role in developing the transcriptomics market. Understanding the various factors contributing to a thriving disease diagnosis is becoming quicker and more precise due to technologies like NGS. These developments offer unrivaled opportunities to advance the field of data analysis in diagnostics significantly and to expand the global transcriptomics market.
A biomarker is a biological marker that aids in identifying the presence, progression, or efficacy of a disease or treatment. It is an efficient method of disease diagnosis. Expanding biomarker discovery would be essential for diagnosing any disease using transcriptomics. The process of developing new medications is multidisciplinary and systematic. Microarrays, next-generation sequencing, and RNA-sequencing have facilitated the discovery of biomarkers in diseases and their drug targets. Various research fields currently employ these techniques, including biological, medical, clinical, and pharmaceutical. RNA-sequencing is advantageous for detecting biomarkers and drug discovery due to the development of detection technology and improved analytical methods, which have increased its applications.
The North American region dominates the global transcriptomics market. The prevalence of cancer, infectious diseases, and chronic diseases and the presence of established pharmaceutical players are driving the North American transcriptomics market. The U.S. transcriptomics market is driven by rising demand for RNA-based NGS. NGS technology is relied upon by manufacturers to provide a complete picture of diseases at the gene and cell levels. Research institutions are also developing new protocols for cell analysis, revolutionizing biomedical research. This is anticipated to increase NGS use in the United States for diagnostic and therapeutic purposes.
sales@straitsresearch.com